Clinical Scenario

This protocol addresses thymic carcinoma staged as Masaoka-Koga stage IVB (TNM stage IVB), where the disease has disseminated to distant sites via lymphogenous or haematogenous spread. At this stage, resection and radiotherapy are no longer applicable as definitive treatments, and systemic therapy becomes the sole treatment modality.

First-Line Treatment Approach

The approach at this stage is built around a definitive cisplatin-based multiagent combination chemotherapy regimen. The specific agents and preferred combinations differ between thymoma and thymic carcinoma histology — the complete regimen selection, sequencing, and full decision framework are available in the full protocol.

Treatment Goals

The primary aim is to relieve tumour-related symptoms through tumour shrinkage. Response to chemotherapy is evaluated using RECIST v1.1 criteria.

References

DOI: 10.1093/annonc/mdv277

Treatment algorithm for metastatic thymic tumour (Masaoka-Koga stage IVB, TNM stage IVB).
Chemotherapy should be offered as single modality treatment in advanced, non-resectable, non-irradiable or metastatic (stage IVB) thymic epithelial tumours.
Cisplatin-based combination regimens should be administered [III, A] (Table 6).
The aim is to relieve tumour-related symptoms by eliciting tumour shrinkage, while prolonged survival is uncertain [III, A].
Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 criteria should be used to assess response to chemotherapy [V, A].

View source ↗

Treatment of Thymic Carcinoma at Masaoka-Koga Stage IVB (TNM Stage IVB) with Distant Metastasis

Clinical Scenario

First-Line Treatment Approach

Treatment Goals

References